Impact of prothrombin time-International Normalized Ratio on outcome of patients with septic shock receiving polymyxin B cartridge hemoperfusion

被引:8
作者
Isbizuka, Mitsuru [1 ]
Tago, Kazuma [1 ]
Kubota, Keilichi [1 ]
机构
[1] Dokkyo Med Univ, Dept Surg Gastroenterol, Mibu, Tochigi 3210293, Japan
关键词
DISSEMINATED INTRAVASCULAR COAGULATION; IMMOBILIZED FIBER COLUMN; CONTINUOUS VENOVENOUS HEMOFILTRATION; SEVERE SEPSIS; PROTEASE INHIBITOR; ANTITHROMBIN-III; COMPLICATION; MANAGEMENT; SURVIVAL; EFFICACY;
D O I
10.1016/j.surg.2014.03.009
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Although most patients with septic shock have a poor outcome, some may survive after blood purification treatment such as polymyxin B cartridge hemoperfusion (PMX). Objective. To explore the most significant characteristic associated with 28-day mortality in patients with septic shock receiving PMX. Methods. Between April 2006 and March 2008, 116 patients with septic shock who had received PMX in a prospectively collected multicenter collaborative study were enrolled. Uni- and multivariate analyses Wing the Cox proportional hazard model were performed to assess the most significant clinical characteristic that was associated with 28-day mortality. Results. Among 33 clinicolaboratory characteristics, receiver operating characteristic (ROC) curve analyses Selected 12 characteristics with recommended cutoff values such as HCO3- (<= 19.81/>19.8; mEq/L), base excess (<=-5.35/>-5.35; mEq/L), diastolic blood pressure (<= 48/>48 mmHg), mean arterial pressure (<= 73/>73 mmHg), pH (<= 7.29/>7.29), interleukin-6 (<= 19,150/>19,150 pg/dL), prothrombin time International Normalized Ratio (PT-INR; <= 2.05/>2.05), predictive value of Acute Physiology and Chronic Health Evaluation II (APACHE II; <= 0.4/>0.4), pyruvate (<= 1.82/>1.82 mg/dL),. APACHE II score (<= 21/>21), acetate/pyruvate ratio (<= 19/>19), and acetate (<= 44.8/>44.8 mg/dL) on the basis of large area under the ROC curves for 28-day mortality. The results of uni- and multivariate analyses using these selected characteristics revealed that only PT-INR (<= 2.05/>2.05; hazard ratio, 2.823; 95% CI, 1.243-6.412; P = .013) was associated with 28-day mortality. Survival curve analysis demonstrated a significant difference in 28-day mortality between patients with lower (<= 2.05) and higher (>2.05) PT-INR (P < .001). Conclusion. Prolonged PT-INR is an independent risk factor for 28-day mortality in patients receiving PMX for septic shock.
引用
收藏
页码:168 / 175
页数:8
相关论文
共 32 条
[1]   THROMBOMODULIN ALFA IN THE TREATMENT OF INFECTIOUS PATIENTS COMPLICATED BY DISSEMINATED INTRAVASCULAR COAGULATION: SUBANALYSIS FROM THE PHASE 3 TRIAL [J].
Aikawa, Naoki ;
Shimazaki, Shuji ;
Yamamoto, Yasuhiro ;
Saito, Hidehiko ;
Maruyama, Ikuro ;
Ohno, Ryuzo ;
Hirayama, Akio ;
Aoki, Yoshikazu ;
Aoki, Nobuo .
SHOCK, 2011, 35 (04) :349-354
[2]   Lipopolysaccharide binding protein in cirrhotic patients with severe sepsis [J].
Chen, Yi-Yuan ;
Lien, Jau-Min ;
Peng, Yun-Shing ;
Chen, Yung-Chang ;
Tian, Ya-Chung ;
Fang, Ji-Tseng ;
Huang, Hsing-Chih ;
Chen, Pang-Chi ;
Yang, Chih-Wei ;
Wu, Cheng-Shyong ;
Tsai, Ming-Hung .
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2014, 77 (02) :68-74
[3]   Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review [J].
Cruz, Dinna N. ;
Perazella, Mark A. ;
Bellomo, Rinaldo ;
de Cal, Massimo ;
Polanco, Natalia ;
Corradi, Valentina ;
Lentini, Paolo ;
Nalesso, Federico ;
Ueno, Takuya ;
Ranieri, V. Marco ;
Ronco, Claudio .
CRITICAL CARE, 2007, 11 (02)
[4]   Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock The EUPHAS Randomized Controlled Trial [J].
Cruz, Dinna N. ;
Antonelli, Massimo ;
Fumagalli, Roberto ;
Foltran, Francesca ;
Brienza, Nicola ;
Donati, Abele ;
Malcangi, Vincenzo ;
Petrini, Flavia ;
Volta, Giada ;
Pallavicini, Franco M. Bobbio ;
Rottoli, Federica ;
Giunta, Francesco ;
Ronco, Claudio .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (23) :2445-2452
[5]  
De Vriese AS, 1999, J AM SOC NEPHROL, V10, P846
[6]   Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 [J].
Dellinger, R. Phillip ;
Levy, Mitchell M. ;
Carlet, Jean M. ;
Bion, Julian ;
Parker, Margaret M. ;
Jaeschke, Roman ;
Reinhart, Konrad ;
Angus, Derek C. ;
Brun-Buisson, Christian ;
Beale, Richard ;
Calandra, Thierty ;
Dhainaut, Jean-Francois ;
Gerlach, Herwig ;
Harvey, Maurene ;
Marini, John J. ;
Marshall, John ;
Ranieri, Marco ;
Ramsay, Graham ;
Sevransky, Jonathan ;
Thompson, B. Taylor ;
Townsend, Sean ;
Vender, Jeffrey S. ;
Zimmerman, Janice L. ;
Vincent, Jean-Louis .
CRITICAL CARE MEDICINE, 2008, 36 (01) :296-327
[7]  
DELLINGER RP, 2013, INTENS CARE MED, V39, P165, DOI DOI 10.1007/s00134-012-2769-8
[8]   THE INHIBITORY EFFECT OF POLYMYXIN-B ON ENDOTOXIN-INDUCED ENDOGENOUS PYROGEN PRODUCTION [J].
DUFF, GW ;
ATKINS, E .
JOURNAL OF IMMUNOLOGICAL METHODS, 1982, 52 (03) :333-340
[9]   Antithrombin III in patients with severe sepsis - A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis [J].
Eisele, B ;
Lamy, M ;
Thijs, LG ;
Keinecke, HO ;
Schuster, HP ;
Matthias, FR ;
Fourrier, F ;
Heinrichs, H ;
Delvos, U .
INTENSIVE CARE MEDICINE, 1998, 24 (07) :663-672
[10]  
Gando S, 1996, THROMB HAEMOSTASIS, V75, P224